{
    "root": "8cc23541-0457-4fc2-8098-4cdf8f5a0d1a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "leflunomide",
    "value": "20241030",
    "ingredients": [
        {
            "name": "LEFLUNOMIDE",
            "code": "G162GK9U4W",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6402"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        }
    ],
    "indications": {
        "text": "leflunomide tablets , usp indicated treatment adults active rheumatoid arthritis ( rheumatoid arthritis ) .",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "loading patients low risk leflunomide -associated hepatotoxicity leflunomide -associated myelosuppression : 100 mg daily 3 days . ( 2.1 ) maintenance : 20 mg daily . ( 2.1 ) maximum recommended daily : 20 mg daily . ( 2.1 ) 20 mg daily tolerated , may decrease 10 mg daily . ( 2.1 ) screen patients active latent tuberculosis , pregnancy test ( females ) , blood pressure , laboratory tests starting leflunomide tablets . ( 2.2 )",
        "doid_entities": [
            {
                "text": "tuberculosis (DOID:399)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_399"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "leflunomide tablets , usp 10 mg - white , round bi-convex tablet debossed `` hp 43 `` one side plain . ndc : 72162-2409-3 : 30 tablets bottle store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . protect light . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "leflunomide tablets contraindicated : \u2022pregnant women . leflunomide may cause fetal harm . woman becomes pregnant taking , stop leflunomide , apprise patient potential hazard fetus , begin elimination procedure [ ( 5.1and 5.3 ) ( 8.1 ) ] . \u2022patients severe hepatic impairment [ ( 5.2 ) ] . \u2022patients known hypersensitivity leflunomide components leflunomide tablets . known include anaphylaxis [ ( 6.1 ) ] . \u2022patients treated teriflunomide [ ( 7 ) ] .",
    "indications_original": "Leflunomide tablets, USP are indicated for the treatment of adults with active rheumatoid arthritis (RA).",
    "contraindications_original": "Loading dosage for patients at low risk for leflunomide -associated hepatotoxicity and leflunomide -associated myelosuppression: 100 mg daily for 3 days. ( 2.1 ) Maintenance dosage: 20 mg daily. ( 2.1 ) Maximum recommended daily dosage: 20 mg once daily. ( 2.1) If 20 mg once daily is not tolerated, may decrease dosage to 10 mg once daily. ( 2.1 ) Screen patients for active and latent tuberculosis, pregnancy test (females), blood pressure, and laboratory tests before starting leflunomide tablets . ( 2.2 )",
    "warningsAndPrecautions_original": "Leflunomide Tablets, USP\n                  10 mg -\u00a0White, round bi-convex tablet debossed with \"HP 43\" on one side and plain on the other.\n                  NDC: 72162-2409-3: 30 Tablets in a BOTTLE\n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. Protect from light.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Leflunomide tablets are contraindicated in:\n                  \u2022Pregnant women.\u00a0 Leflunomide may cause fetal harm.\u00a0 If a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see Warnings and Precautions (5.1and 5.3) and Use in Specific Populations (8.1)].\n                  \u2022Patients with severe hepatic impairment [see Warnings and Precautions (5.2)].\n                  \u2022Patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. Known reactions include anaphylaxis [see Adverse Reactions (6.1)].\n                  \u2022Patients being treated with teriflunomide [see Drug Interactions (7)].",
    "drug": [
        {
            "name": "leflunomide",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6402"
        }
    ]
}